Evotec SE reached another program designation in its neuroscience collaboration with Bristol Myers Squibb, triggering a payment of $16 million to Evotec.   The program further adds to a growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development at the end of 2021. While the previously nominated programs are small molecule based, the new project uses an antisense-based approach. Evotec is eligible to receive royalties and percentages of sales of any com...